C. Griffiths

Publications789
h-index100
Citations40,085
Highly Influential Citations1,123
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Voorhees
  • 759 Publications • 47,275 Citations
  • J. Barker
  • 438 Publications • 24,818 Citations
  • R. Warren
  • 350 Publications • 8,553 Citations
  • K. Reich
  • 602 Publications • 26,808 Citations
  • Publications
  • Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
TLDR
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
View on PubMed
Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
TLDR
The data indicated that the occurrence of psoriasis varied according to age and geographic region, being more frequent in countries more distant from the equator and trends in incidence over time.
View on PubMed
Psoriasis: epidemiology, clinical features, and quality of life
TLDR
The epidemiology, clinical features, and impact on quality of life of psoriasis are reviewed.
View on BMJ
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
TLDR
Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
View on Wiley
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
View on Elsevier
Pathogenesis and clinical features of psoriasis
View on Elsevier
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
TLDR
The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
View on PubMed
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
View on Elsevier
Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the…
View on Wolters Kluwer
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
TLDR
Background  In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated and a well tolerated drug.
View on Wiley
...
...